A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibitions

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 1, 2013, Pages 76-84

  Kobayashi, Yoshiki ^a   Wada, Hiroo ^b   Rossios, Christos ^a   Takagi, Dai ^a   Higaki, Manabu ^b   Mikura, Shin'ichiro ^b   Goto, Hajime ^b   Barnes, Peter J ^a   Ito, Kazuhiro ^a,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KYORIN UNIVERSITY   (Japan)

^c RespiVert Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; SOLITHROMYCIN; TELITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-8; MACROLIDES; MACROPHAGES, ALVEOLAR; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NF-KAPPA B; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TOBACCO SMOKE POLLUTION; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 84875413952     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.200733     Document Type: Article

References (59)

1. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K, and Tomoike H (2000) Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 22:51-60.
2. Aghai ZH, Kode A, Saslow JG, Nakhla T, Farhath S, Stahl GE, Eydelman R, Strande L, Leone P, and Rahman I (2007) Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res 62:483-488.
3. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, and Lazarus SC, et al. COPD Clinical Research Network (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365: 689-698.
4. Banerjee D, Khair OA, and Honeybourne D (2005) The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 99:208-215.
5. Barnes PJ (2009) The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 41:631-638.
6. Bertrand D, Bertrand S, Neveu E, and Fernandes P (2010) Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother 54:5399-5402.
7. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, and Guffanti E (2010) Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 23:200-207.
8. Bosnar M, Bosnjak B, Cuzic S, Hrvacic B, Marjanovic N, Glojnaric I, Culic O, Parnham MJ, and Erakovic Haber V (2009) Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta. J Pharmacol Exp Ther 331:104-113.
9. Bosnar M, Čužić S, Bošnjak B, Nujić K, Ergović G, Marjanović N, Pašalić I, Hrvačić B, Polančec D, and Glojnarić I, et al. (2011) Azithromycin inhibits macrophage interleukin-1b production through inhibition of activator protein-1 in lipopolysaccharideinduced murine pulmonary neutrophilia. Int Immunopharmacol 11:424-434.
10. Desaki M, Okazaki H, Sunazuka T, Omura S, Yamamoto K, and Takizawa H (2004) Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation. Antimicrob Agents Chemother 48:1581-1585.
11. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, and Ito K (2000) Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 267:124-128.
12. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, and Jones RN (2010) Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents 35:537-543.
13. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, and D'Armiento J (2008) Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 294:L1149-L1157.
14. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, and Zhong XN (2010) Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 80:445-452.
15. Iino Y, Toriyama M, Kudo K, Natori Y, and Yuo A (1992) Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl 157:16-20.
16. Inamura K, Ohta N, Fukase S, Kasajima N, and Aoyagi M (2000) The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 38:124-129.
17. Ito K and Barnes PJ (2009) COPD as a disease of accelerated lung aging. Chest 135: 173-180.
18. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, and Nieman RB; TELICAST Investigators (2006) The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354:1589-1600.
19. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, and Kohno S (2003) Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97:844-850.
20. Kamemoto A, Ara T, Hattori T, Fujinami Y, Imamura Y, and Wang PL (2009) Macrolide antibiotics like azithromycin increase lipopolysaccharide-induced IL-8 production by human gingival fibroblasts. Eur J Med Res 14:309-314.
21. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Kadota J, and Kohno S (2003) Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 285:L847-L853.
22. Kanoh S and Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23:590-615.
23. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A, and Nukiwa T (2002) Clarithromycin suppresses lipopolysaccharideinduced interleukin-8 production by human monocytes through AP-1 and NFkappa B transcription factors. J Antimicrob Chemother 49:745-755.
24. Kobayashi Y, Mercado N, Barnes PJ, and Ito K (2011) Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. PLoS ONE 6:e27627.
25. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, and Ito K (1999) Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 43:907-911.
26. Korematsu S, Yamamoto K, Nagakura T, Miyahara H, Okazaki N, Akiyoshi K, Maeda T, Suenobu S, and Izumi T (2010) The indication and effectiveness of lowdose erythromycin therapy in pediatric patients with bronchial asthma. Pediatr Allergy Immunol 21:489-492.
27. Kudoh S, Azuma A, Yamamoto M, Izumi T, and Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157:1829-1832.
28. Kurdowska A, Noble JM, and Griffith DE (2001) The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. J Antimicrob Chemother 47:867-870.
29. Leiva M, Ruiz-Bravo A, and Jimenez-Valera M (2008) Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 134:20-29.
30. Li M, Zhong X, He Z, Wen M, Li J, Peng X, Liu G, Deng J, Zhang J, and Bai J (2012) Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-kB activity in human macrophages in vitro. Int Immunopharmacol 12:643-650.
31. Lin SJ, Lee WJ, Liang YW, Yan DC, Cheng PJ, and Kuo ML (2011) Azithromycin inhibits IL-5 production of T helper type 2 cells from asthmatic children. Int Arch Allergy Immunol 156:179-186.
32. Marjanović N, Bosnar M, Michielin F, Willé DR, Anić-Milić T, Culić O, Popović-Grle S, Bogdan M, Parnham MJ, and Eraković Haber V (2011) Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 63:389-397.
33. Matsumura Y, Mitani A, Suga T, Kamiya Y, Kikuchi T, Tanaka S, Aino M, and Noguchi T (2011) Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide. J Periodontol 82:1623-1631.
34. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, and Appelbaum PC (2010) In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 54:230-238.
35. Meyer M, Huaux F, Gavilanes X, van den Brûle S, Lebecque P, Lo Re S, Lison D, Scholte B, Wallemacq P, and Leal T (2009) Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 41:590-602.
36. Mikura S, Wada H, Higaki M, Yasutake T, Ishii H, Kamiya S, and Goto H (2011) Erythromycin prevents the pulmonary inflammation induced by exposure to cigarette smoke. Transl Res 158:30-37.
37. Morikawa T, Kadota JI, Kohno S, and Kondo T (2000) Superoxide dismutase in alveolar macrophages from patients with diffuse panbronchiolitis. Respiration 67: 546-551.
38. Mukae H, Kadota J, Ashitani J, Taniguchi H, Mashimoto H, Kohno S, and Matsukura S (1997) Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 112:1615-1621.
39. Nakamaru Y, Vuppusetty C, Wada H, Milne JC, Ito M, Rossios C, Elliot M, Hogg J, Kharitonov S, and Goto H, et al. (2009) A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 23:2810-2819.
40. Nakanishi Y, Kobayashi D, Asano Y, Sakurai T, Kashimura M, Okuyama S, Yoneda Y, Shapiro SD, and Takayama K (2009) Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 179:271-278.
41. Oda H, Kadota J, Kohno S, and Hara K (1995) Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 108:116-122.
42. Ogawa M, Suzuki J, Takayama K, and Isobe M (2009) Matrix metalloproteinase suppression induced by clarithromycin in murine cardiac allografts. Transplant Proc 41:395-397.
43. Ohbayashi H (2002) Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 3:409-421.
44. Rahman I and Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28:219-242.
45. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, and O'Neal WK (2009) Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS ONE 4:e5806.
46. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, and Barnes PJ (2002) Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 26:602-609.
47. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, and Hara K (1996) Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 63:42-48.
48. Schultz MJ (2004) Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54:21-28.
49. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, and Wedzicha JA (2008) Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 178: 1139-1147.
50. Shinkai M, Foster GH, and Rubin BK (2006) Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 290:L75-L85.
51. Simpson JL, Phipps S, and Gibson PG (2009) Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. Pharmacol Ther 124:86-95.
52. Simpson JL, Powell H, Boyle MJ, Scott RJ, and Gibson PG (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177:148-155.
53. Stankiewicz W, Dabrowski MP, Chcialowski A, and Plusa T (2002) Cellular and cytokine immunoregulation in patients with chronic obstructive pulmonary disease and bronchial asthma. Mediators Inflamm 11:307-312.
54. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Tanaka M, Kasama T, Kobayashi K, and Nakajima J, et al. (1997) Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 156:266-271.
55. Tamaoki J, Kadota J, and Takizawa H (2004) Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117 (Suppl 9A):5S-11S.
56. Tateda K, Standiford TJ, Pechere JC, and Yamaguchi K (2004) Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des 10:3055-3065.
57. Trisolini R, Cancellieri A, Paioli D, Burzi M, Orlandi P, and Patelli M (2008) Sarcoidosis in the setting of idiopathic chronic bronchiolitis with airway colonization from P. aeruginosa: treatment with low-dose macrolides. Intern Med 47:537-542.
58. Tsuchihashi Y, Oishi K, Yoshimine H, Suzuki S, Kumatori A, Sunazuka T, Omura S, Matsushima K, and Nagatake T (2002) Fourteen-member macrolides suppress interleukin-8 production but do not promote apoptosis of activated neutrophils. Antimicrob Agents Chemother 46:1101-1104.
59. Vernooy JH, Küçükaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, and Wouters EF (2002) Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 166:1218-1224.